Redwood City, California, United States PMV Pharmaceuticals appeared to be the Corporate Investor, which was created in 2013. The leading representative office of defined Corporate Investor is situated in the Redwood City. The company was established in North America in United States.
The standard case for the fund is to invest in rounds with 4 partakers. Despite the PMV Pharmaceuticals, startups are often financed by Vinnof, Vesalius Biocapital Partners. The meaningful sponsors for the fund in investment in the same round are Vesalius Biocapital Partners, Limburgse Reconversie Maatschappij, Wyvern Seed Fund.
The fund has exact preference in a number of founders of portfolio startups. Among the most popular fund investment industries, there are Biotechnology, Pharmaceutical. Besides, a startup needs to be aged 6-10 years to get the investment from the fund. For fund there is no match between the country of its foundation and the country of its the most frequent investments - United Kingdom. Among the most popular portfolio startups of the fund, we may highlight FF Pharma, Apitope.
The fund was created by Arnold Levine, David Mack, Thomas Shenk.
The high activity for fund was in 2015. The fund is generally included in less than 2 deals every year. The common things for fund are deals in the range of 5 - 10 millions dollars.
| Fund Name | Location |
| CEC Data Capital | Beijing, Beijing, China |
| Contemporary Amperex Technology | China, Qinghai, Xining |
| Cresco Capital Partners | Dallas, Texas, United States |
| Data Capital Management | New York, New York, United States |
| Jiu Gua Gua | Beijing, Beijing, China |
| Map Master | Aichi Prefecture, Japan, Nagoya |
| Perot Investments | Plano, Texas, United States |
| Stand Together Ventures Lab | - |
| Vineyard Point Associates | - |
Notable deals
| Company | Industry | Round Size | Date | Investors | Location |
Apitope | $14M | 29 Sep 2015 | England | ||
FF Pharma | $4M | 23 Jan 2013 | Utrecht |
1. You post comments at your own choice and risk. You bear the whole responsibility,related to their substance, content and the fact of publication. We shall not bear anyliability in respect of such comments.
2. While commenting, you shall use only actual, truthful and confirmed data. In thesame time you shall not use vulgar, abusive or defamatory language as well as expresshatred or call to violence or cruelty.
3. We do not intend to delete any comments on the website unless within our “noticeand take down” procedure.
4. We can moderate comments at any time.
5. While commenting, you are under the rule of our website’s terms of use and privacypolicy.
6. We retain our right to delete any comment or any other content of the website at ourwill in case we know or suppose such content is illegal or breaches any lawful right.
Review
- No reviews are submitted yet.
Sign up and get access to full fund profile and advanced analysis.
Full teamIndustries heatmapStages heatmapGeorgaphy breakdownCoinvestorsPortfolio analysisPerformance indexesLatest highlights
Unlock all data Latest deals
| Company | Industry | Round Size | Date | Investors | Location |
Apitope | $14M | 29 Sep 2015 | England | ||
FF Pharma | $4M | 23 Jan 2013 | Utrecht |
